Seely Lynn's Form 4 filing
Lyell Immunopharma, Inc. (LYEL) · filed Aug 11, 2026
- Accession no.
- 0001327111-26-000004
- Filed
- Aug 11, 2026, 4:07 PM ET
- Trade date
- Aug 10, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $5.59K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Seely LynnCIK 0001327111 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | SSaleDisposed | −390 | $14.34 | −$5,592.6 | 73,488 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.